Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2005-11-03
2009-02-24
Shiao, Rei-tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S121000, C558S177000, C558S178000
Reexamination Certificate
active
07494985
ABSTRACT:
Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, pharmaceutical compositions comprising acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, methods of making prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, methods of using prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof and pharmaceutical compositions thereof for treating or preventing diseases or disorders such as spasticity or gastroesophageal reflux disease are disclosed. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof and sustained release oral dosage forms thereof, which are suitable for oral administration, are also disclosed.
REFERENCES:
patent: 2996431 (1961-08-01), Barry
patent: 3139383 (1964-06-01), Neville
patent: 3402240 (1968-09-01), Cain et al.
patent: 3803112 (1974-04-01), Engelhardt et al.
patent: 3811444 (1974-05-01), Heller et al.
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3962414 (1976-06-01), Michaels
patent: 3992518 (1976-11-01), Chien et al.
patent: 4063064 (1977-12-01), Saunders et al.
patent: 4066747 (1978-01-01), Capozza
patent: 4070347 (1978-01-01), Schmitt
patent: 4079038 (1978-03-01), Choi et al.
patent: 4083949 (1978-04-01), Benedikt
patent: 4088864 (1978-05-01), Theeuwes et al.
patent: 4093709 (1978-06-01), Choi et al.
patent: 4126684 (1978-11-01), Robson et al.
patent: 4200098 (1980-04-01), Ayer et al.
patent: 4285987 (1981-08-01), Ayer et al.
patent: 4421736 (1983-12-01), Walters
patent: 4434153 (1984-02-01), Urquhart et al.
patent: 4656298 (1987-04-01), Dingwall et al.
patent: 4721613 (1988-01-01), Urquhart et al.
patent: 4752470 (1988-06-01), Mehta
patent: 4816263 (1989-03-01), Ayer et al.
patent: 4820523 (1989-04-01), Shtohryn et al.
patent: 4853229 (1989-08-01), Theeuwes
patent: 4996058 (1991-02-01), Sinnreich
patent: 5006560 (1991-04-01), Kreutner et al.
patent: 5013863 (1991-05-01), Baylis et al.
patent: 5051524 (1991-09-01), Baylis et al.
patent: 5091184 (1992-02-01), Khanna
patent: 5229135 (1993-07-01), Philippon et al.
patent: 5229379 (1993-07-01), Marescaux et al.
patent: 5281747 (1994-01-01), Hall et al.
patent: 5300679 (1994-04-01), Baylis et al.
patent: 5332729 (1994-07-01), Mickel et al.
patent: 5376684 (1994-12-01), Mickel
patent: 5407922 (1995-04-01), Marescaux
patent: 5424441 (1995-06-01), Mickel et al.
patent: 5461040 (1995-10-01), Hall et al.
patent: 5545631 (1996-08-01), Marescaux et al.
patent: 5567840 (1996-10-01), Hall et al.
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 5719185 (1998-02-01), Bountra et al.
patent: 6117908 (2000-09-01), Andrews et al.
patent: 6171615 (2001-01-01), Roussin et al.
patent: 6375987 (2002-04-01), Farah et al.
patent: 6379700 (2002-04-01), Joachim et al.
patent: 6627223 (2003-09-01), Percel et al.
patent: 6664069 (2003-12-01), Andrews et al.
patent: 7319110 (2008-01-01), Lange et al.
patent: 2002/0187977 (2002-12-01), Pearlman et al.
patent: 2003/0162754 (2003-08-01), Ligon
patent: 2004/0152775 (2004-08-01), Fitzpatrick et al.
patent: 2006/0111325 (2006-05-01), Gallop
patent: 2006/0111439 (2006-05-01), Gallop
patent: 2008/0146526 (2008-06-01), Gallop et al.
patent: WO 00/57862 (2000-10-01), None
patent: WO 01/08675 (2001-02-01), None
patent: WO 01/26638 (2001-04-01), None
patent: WO 01/42252 (2001-06-01), None
patent: WO 01/54481 (2001-08-01), None
patent: WO 02/096404 (2002-12-01), None
patent: WO 02/100347 (2002-12-01), None
patent: WO 02/100392 (2002-12-01), None
patent: WO 02/100823 (2002-12-01), None
patent: WO 02/100869 (2002-12-01), None
patent: WO 02/100870 (2002-12-01), None
patent: WO 02/100871 (2002-12-01), None
patent: WO 03/011255 (2003-02-01), None
patent: WO 2004/000855 (2003-12-01), None
patent: WO 2004/000856 (2003-12-01), None
patent: WO 2005/010011 (2005-02-01), None
patent: WO 2005/019163 (2005-03-01), None
patent: WO 2005/066122 (2005-07-01), None
patent: WO 2006/050471 (2006-05-01), None
patent: WO 2008/033572 (2008-03-01), None
U.S. Appl. No. 11/265,204, filed Nov. 3, 2005, Gallop.
Alderman,Int. J. Pharm. Tech.&Prod. Mfr., 1984, 5(3), 1-9.
Bamba et al.,Int. J. Pharm., 1979, 2, 307-315.
Bowery, “Commercial and Pipeline Perspectives: Upper GI Disorders,”DataMonitor Report, Sep. 2004, p. 147.
Bowery,Trends Pharmacol. Sci., 1989, 10, 401-407.
Cange et al.,Aliment. Pharmacol. Ther., 2002, 16, 869-873.
Carruthers et al.,Bioorg. Med. Chem. Lett., 1995, 5, 237-240.
Carruthers et al.,Bioorg. Med. Chem. Lett., 1998, 8, 3059-3064.
Cercós-Fortea et al.,Biopharm. Drug. Disp., 1995, 16, 563-577.
Ciccaglione et al.,Gut, 2003, 52, 464-470.
Coleman et al.,Polymers, 1990, 31, 1187-1203.
Deguchi et al.,Pharm. Res., 1995, 12, 1838-1844.
During et al.,Ann. Neurol., 1989, 25, 351-356.
Fincher,J. Pharm. Sci., 1968, 57, 1825-1835.
Froestl et al.,J. Med. Chem., 1995, 38, 3297-3312.
Goodson, in “Medical Applications of Controlled Release,” vol. 2, pp. 115-138, 1984.
Green et al., “Protective Groups in Organic Chemistry,” Wiley, 2nded. 1991 (Table of Contents).
Harrison et al., “Compendium of Synthetic Organic Methods,” vols. 1-8, John Wiley and Sons, 1971-1996 (Table of Contents).
Howard et al.,J. Neurosurg., 1989, 71, 105-112.
Koek et al.,Gut, 2003, 52, 1397-1402.
Langer and Wise (eds.), “Medical Applications of Controlled Release,” vol. I and II CRC Press., Boca Raton, Florida, 1974 (Table of Contents).
Langer, Sefton,CRC Crit Ref Biomed. Eng., 1987, 14, 201-240.
Langer,Science, 1990, 249, 1527-1533.
Langer et al.,J Macromol. Sci. Rev. Macromol Chem. Phys., 1983, 23, 61-126.
Larock “Comprehensive Organic Transformations,” VCH Publishers, 1989.
Leong et al.,Adv. Drug Delivery Rev., 1987, 1, 199-233.
Levy et al.,Science, 1985, 228, 190-192.
Lidums et al.,Gastroenterology, 2000, 118, 7-13.
Lu,Int. J. Pharm., 1994, 112, 117-124.
Merino et al.,Biopharm. Drug. Disp., 1989, 10, 279-297.
Misgeld et al.,Prog. Neurobiol., 1995, 46, 423-462.
Mittal et al.,Gastroenterology, 1995, 109, 601-610.
Moll-Navarro et al.,J. Pharm. Sci., 1996, 85, 1248-1254.
Paquette (ed.), “Encyclopedia of Reagents for Organic Synthesis,” John Wiley & Sons, 1995 (Table of Contents).
“Remington's Pharmaceutical Sciences,” Lippincott Williams & Wilkins, 21st Edition, 2005 (Table of Contents).
Roerdink et al.,Drug Carrier Systems, 1989, 9, 57-109.
Roff et al.,Handbook of Common Polymers, CRC Press, 1971 (Table of Contents).
Rosoff,Controlled Release of Drugs, Chap. 2, pp. 53-95, 1989.
Saudek et al.,N. Engl. J Med., 1989, 321, 574-579.
Shue et al.,Bioorg. Med. Chem. Lett., 1996, 6, 1709-1714.
Smolen and Ball (eds.), “Controlled Drug Bioavailability: Drug Product Design and Performance,” Wiley, New York, 1984 (Table of Contents).
Tonini et al.,Drugs, 2004, 64, 347-361.
van Bree et al.,Pharm. Res., 1988, 5, 369-371.
van Herwaarden et al.,Aliment. Pharmacol. Ther., 2002, 16, 1655-1662.
Vela et al.,Aliment. Pharmacol. Ther., 2003, 17, 243-251.
Verma et al.,Drug Dev. Ind. Pharm., 2000, 26, 695-708.
Zhang et al.,Gut, 2002, 50, 19-24.
Li et al., “Synthesis of (alkoxycarbonyloxy)methyl, (acyloxy)methyl and (oxodioxolenyl)methyl carbamates as bioreversible prodrug moieties for amines,”Bioorganic&Medicinal Chemistry Letters, 7:2909-2912 (1997).
PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, dated Jun. 6, 2006, for Application No. PCT/US2005/039872.
PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, dated May 17, 2006, for Application No. PCT/US2005/039871.
Bardgett et al., NMDA receptor blockade and hippocampal neuronal loss impair fear conditioning and position habit reversal i
Finnegan Henderson Farabow Garrett & Dunner LLP
Shiao Rei-tsang
XenoPort, Inc.
LandOfFree
Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4100066